Cargando…
Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate
BACKGROUND: Pooled human platelet lysate (pHPL) is an efficient alternative to xenogenic supplements for ex vivo expansion of mesenchymal stem cells (MSCs) in clinical studies. Currently, porcine heparin is used in pHPL-supplemented medium to prevent clotting due to plasmatic coagulation factors. We...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641400/ https://www.ncbi.nlm.nih.gov/pubmed/26554451 http://dx.doi.org/10.1186/s12967-015-0717-4 |
_version_ | 1782400197132812288 |
---|---|
author | Laner-Plamberger, Sandra Lener, Thomas Schmid, Doris Streif, Doris A. Salzer, Tina Öller, Michaela Hauser-Kronberger, Cornelia Fischer, Thorsten Jacobs, Volker R. Schallmoser, Katharina Gimona, Mario Rohde, Eva |
author_facet | Laner-Plamberger, Sandra Lener, Thomas Schmid, Doris Streif, Doris A. Salzer, Tina Öller, Michaela Hauser-Kronberger, Cornelia Fischer, Thorsten Jacobs, Volker R. Schallmoser, Katharina Gimona, Mario Rohde, Eva |
author_sort | Laner-Plamberger, Sandra |
collection | PubMed |
description | BACKGROUND: Pooled human platelet lysate (pHPL) is an efficient alternative to xenogenic supplements for ex vivo expansion of mesenchymal stem cells (MSCs) in clinical studies. Currently, porcine heparin is used in pHPL-supplemented medium to prevent clotting due to plasmatic coagulation factors. We therefore searched for an efficient and reproducible medium preparation method that avoids clot formation while omitting animal-derived heparin. METHODS: We established a protocol to deplete fibrinogen by clotting of pHPL in medium, subsequent mechanical hydrogel disruption and removal of the fibrin pellet. After primary culture, bone-marrow and umbilical cord derived MSCs were tested for surface markers by flow cytometry and for trilineage differentiation capacity. Proliferation and clonogenicity were analyzed for three passages. RESULTS: The proposed clotting procedure reduced fibrinogen more than 1000-fold, while a volume recovery of 99.5 % was obtained. All MSC types were propagated in standard and fibrinogen-depleted medium. Flow cytometric phenotype profiles and adipogenic, osteogenic and chondrogenic differentiation potential in vitro were independent of MSC-source or medium type. Enhanced proliferation of MSCs was observed in the absence of fibrinogen but presence of heparin compared to standard medium. Interestingly, this proliferative response to heparin was not detected after an initial contact with fibrinogen during the isolation procedure. CONCLUSIONS: Here, we present an efficient, reproducible and economical method in compliance to good manufacturing practice for the preparation of MSC media avoiding xenogenic components and suitable for clinical studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0717-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4641400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46414002015-11-12 Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate Laner-Plamberger, Sandra Lener, Thomas Schmid, Doris Streif, Doris A. Salzer, Tina Öller, Michaela Hauser-Kronberger, Cornelia Fischer, Thorsten Jacobs, Volker R. Schallmoser, Katharina Gimona, Mario Rohde, Eva J Transl Med Research BACKGROUND: Pooled human platelet lysate (pHPL) is an efficient alternative to xenogenic supplements for ex vivo expansion of mesenchymal stem cells (MSCs) in clinical studies. Currently, porcine heparin is used in pHPL-supplemented medium to prevent clotting due to plasmatic coagulation factors. We therefore searched for an efficient and reproducible medium preparation method that avoids clot formation while omitting animal-derived heparin. METHODS: We established a protocol to deplete fibrinogen by clotting of pHPL in medium, subsequent mechanical hydrogel disruption and removal of the fibrin pellet. After primary culture, bone-marrow and umbilical cord derived MSCs were tested for surface markers by flow cytometry and for trilineage differentiation capacity. Proliferation and clonogenicity were analyzed for three passages. RESULTS: The proposed clotting procedure reduced fibrinogen more than 1000-fold, while a volume recovery of 99.5 % was obtained. All MSC types were propagated in standard and fibrinogen-depleted medium. Flow cytometric phenotype profiles and adipogenic, osteogenic and chondrogenic differentiation potential in vitro were independent of MSC-source or medium type. Enhanced proliferation of MSCs was observed in the absence of fibrinogen but presence of heparin compared to standard medium. Interestingly, this proliferative response to heparin was not detected after an initial contact with fibrinogen during the isolation procedure. CONCLUSIONS: Here, we present an efficient, reproducible and economical method in compliance to good manufacturing practice for the preparation of MSC media avoiding xenogenic components and suitable for clinical studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0717-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-10 /pmc/articles/PMC4641400/ /pubmed/26554451 http://dx.doi.org/10.1186/s12967-015-0717-4 Text en © Laner-Plamberger et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Laner-Plamberger, Sandra Lener, Thomas Schmid, Doris Streif, Doris A. Salzer, Tina Öller, Michaela Hauser-Kronberger, Cornelia Fischer, Thorsten Jacobs, Volker R. Schallmoser, Katharina Gimona, Mario Rohde, Eva Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate |
title | Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate |
title_full | Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate |
title_fullStr | Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate |
title_full_unstemmed | Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate |
title_short | Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate |
title_sort | mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641400/ https://www.ncbi.nlm.nih.gov/pubmed/26554451 http://dx.doi.org/10.1186/s12967-015-0717-4 |
work_keys_str_mv | AT lanerplambergersandra mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT lenerthomas mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT schmiddoris mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT streifdorisa mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT salzertina mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT ollermichaela mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT hauserkronbergercornelia mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT fischerthorsten mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT jacobsvolkerr mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT schallmoserkatharina mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT gimonamario mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate AT rohdeeva mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate |